CollPlant Biotechnologies Ltd. (CLGN) Stock

CollPlant Biotechnologies Ltd., a leader in regenerative and aesthetic medicine, specializes in three-dimensional (3D) bioprinting of tissues and organs, as well as medical aesthetics across the United States, Canada, and Europe. The company's innovative products are based on recombinant type I human collagen, produced using proprietary plant-based genetic engineering technology.

CollPlant Biotechnologies' diverse portfolio includes BioInks tailored for 3D printing of tissues and organs, dermal and soft tissue fillers for addressing wrinkles, and 3D bioprinted breast implants aimed at regenerating breast tissue. The company also offers injectable implants to promote breast tissue regeneration, a 3D bioprinted regenerative soft tissue matrix, VergenixSTR for treating tendinopathy, and VergenixFG for advanced wound care, including diabetic ulcers, venous ulcers, pressure ulcers, burns, and other chronic wounds.

Established in 2004 and headquartered in Rehovot, Israel, CollPlant Biotechnologies Ltd. has forged strategic collaborations with industry leaders such as 3D Systems Corporation, CellInk (a BICO Group company), and the Advanced Regenerative Manufacturing Institute. These partnerships underscore the company's commitment to advancing the field of bioprinting and regenerative medicine, leveraging cutting-edge technology to address critical medical challenges globally.